NCT06067997 (POPEIHE) is a clinical trial of pulmonary embolism diagnosis in Hemoptysis, sponsored by Società Italiana di Medicina di Emergenza-Urgenza.

Who is sponsoring NCT06067997?

NCT06067997 is sponsored by Società Italiana di Medicina di Emergenza-Urgenza.

What drugs are being tested in NCT06067997?

Interventions in NCT06067997: pulmonary embolism diagnosis.

What condition does NCT06067997 study?

NCT06067997 studies Hemoptysis, Pulmonary Embolism.

Is NCT06067997 still recruiting?

NCT06067997 is currently completed. Last updated 5 October 2023.

Last reviewed 2023-10-05 · How we verify

NCT06067997: POPEIHE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevalence Of Pulmonary Embolism In Patients With HEmoptysis (POPEIHE)

Completed Last updated 5 October 2023

What this trial tests

trial testing pulmonary embolism diagnosis in Hemoptysis in 550 participants. Completed in 30 August 2023.

Timeline

1 December 2019

Primary endpoint
30 April 2023

30 August 2023

Quick facts

Lead sponsor	Società Italiana di Medicina di Emergenza-Urgenza
Status	Completed
Study type	OBSERVATIONAL
Enrollment	550
Start date	1 December 2019
Primary completion	30 April 2023
Estimated completion	30 August 2023
Sites	1 location across Italy

Drugs / interventions tested

pulmonary embolism diagnosis

Conditions studied

Hemoptysis — all drugs for Hemoptysis →
Pulmonary Embolism — all drugs for Pulmonary Embolism →

Sponsor

Società Italiana di Medicina di Emergenza-Urgenza

Who can join

18 and older, any sex, with Hemoptysis or Pulmonary Embolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Estimation of the incidence of pulmonary embolism in patients presenting to the Emergency Department with hemoptysis.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Validation and implementation of the FLHASc score for risk stratification of patients with hemoptysis in the emergency department.
Pelagatti L, Bartalucci P, Fabiani G, Giannasi G, et al · · 2026 · PMID 41905245 · DOI 10.1016/j.ajem.2026.03.020
Prospective Validation and Clinical Implementation of the FLHAS Score in Patients Presenting with Hemoptysis to the Emergency Department
Pelagatti L, Bartalucci P, Fabiani G, Giannasi G, et al · · 2025 · DOI 10.21203/rs.3.rs-6814737/v1
Diagnosis of pulmonary embolism in patients with haemoptysis: the POPEIHE study.
Vanni S, Bartalucci P, Pelagatti L, Fabiani G, et al · · 2024 · PMID 39469265 · DOI 10.1183/23120541.00180-2024

Verify or expand the search:

Other recruiting trials for Hemoptysis

Currently open trials in the same condition.

NCT05634200 — Utility of Bronchoscopy in Patients With Haemoptysis and Negative Chest CT Scan (ULYSSES) · recruiting
NCT04961528 — ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial. · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06067997 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Società Italiana di Medicina di Emergenza-Urgenza
Last refreshed: 5 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06067997.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing